TNX-355, in combination with optimized background regimen (OBR), achieves statistically significant viral load reduction and CD4 cell count increase when compared with OBR alone in phase 2 study at 48 weeks [abstract].
Déc. 30, 2006
30 Déc. 2006
Norris D, Morales J, Godofsky E, et al.
Location
XVI International AIDS Conference; August 13-18, 2006; Toronto, Ontario, Canada.